Specialty Pharmaceutical Business Investment Opportunities in Częstochowa

• Poland-based pharmaceutical manufacturing company developing a state-of-the-art production facility for pharmaceutical-grade cannabis flos in Częstochowa. • The facility will manufacture medical cannabis raw material for pharmaceutical applications with an estimated initial production capacity of approximately 2,000 kg per month. • Partial commercial operations are expected to commence in the first quarter of next year, with full-scale operations planned for the second quarter. • A Letter of Intent (LOI) has been signed with a pharmaceutical company for the purchase of the raw material, providing an established sales pipeline upon commencement of production. • The business will operate through three revenue streams: production of pharmaceutical-grade medical cannabis in cooperation with a state scientific institute under GMP standards; import of GACP-certified raw material for value-added GMP processing under the company's own certification, with processing capacity of up to 2,000 kg per month; and B2B contract packaging and laboratory testing services for third parties. • The facility will include an advanced physicochemical laboratory equipped with technologies such as HPLC and ICP-MS to support quality control, research, and commercial testing services. • The business is being developed with a scalable manufacturing model designed to serve pharmaceutical companies and other licensed industry participants. • Well positioned to capitalize on the growing demand for pharmaceutical-grade medical cannabis and contract manufacturing services in regulated European markets.

• Poland-based pharmaceutical manufacturing company developing a state-of-the-art production facility for pharmaceutical-grade cannabis flos in Częstochowa. • The facility will manufacture medical cannabis raw material for pharmaceutical applications with an estimated initial production capacity of approximately 2,000 kg per month. • Partial commercial operations are expected to commence in the first quarter of next year, with full-scale operations planned for the second quarter. • A Letter of Intent (LOI) has been signed with a pharmaceutical company for the purchase of the raw material, providing an established sales pipeline upon commencement of production. • The business will operate through three revenue streams: production of pharmaceutical-grade medical cannabis in cooperation with a state scientific institute under GMP standards; import of GACP-certified raw material for value-added GMP processing under the company's own certification, with processing capacity of up to 2,000 kg per month; and B2B contract packaging and laboratory testing services for third parties. • The facility will include an advanced physicochemical laboratory equipped with technologies such as HPLC and ICP-MS to support quality control, research, and commercial testing services. • The business is being developed with a scalable manufacturing model designed to serve pharmaceutical companies and other licensed industry participants. • Well positioned to capitalize on the growing demand for pharmaceutical-grade medical cannabis and contract manufacturing services in regulated European markets.